AI-assisted high-content imaging and toxicity screening using 3D liver organoids
22 Jul 2025
One of the biggest challenges in modern drug discovery is that 90% of candidates fail during development, largely due to safety concerns around liver toxicity. This high failure rate can often be linked to the limitations of traditional 2D cell cultures used in early testing. As a result, there is a critical need to develop more predictive in vitro assays, especially for assessing hepatotoxicity. In this presentation, Dr. Oksana Sirenko, Senior Manager of Assay Development at Molecular Devices, explores how high-content imaging, along with AI and machine learning, can serve as powerful tools to investigate drug effects and predict potential toxicity more accurately.
This video was filmed at SLAS Europe 2025.
About the company
Molecular Devices®
Molecular Devices is one of the world’s leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California, with offices around the globe. For more information, please visit www.moleculardevices.com.
General Inquiry - USA & Canada: +1 800-635-5577 General Inquiry - Europe: 00800 665 32860 Sales +1 877-589-2214 Support +1 800 635 5577
Related products
Request Quote for All Products
CellXpress.ai Automated Cell Culture System
Molecular Devices®The CellXpress.ai™ Automated Cell Culture System is an AI-driven cell culture innovation hub that gives your team total control over demanding cell culture feeding and passaging schedules—eliminating time in the lab while maintaining a 24/7 schedule for growing and scaling multiple stem cell lines, spheroids, or organoids.
